FindTrial
Sign In

Ciltacabtagene Autoleucel

DRUG6 trials

Sponsors

Dana-Farber Cancer Institute, Washington University School of Medicine, St. Olavs Hospital, Mayo Clinic, Medical College of Wisconsin

Conditions

AL AmyloidosisMultiple MyelomaMyeloma MultiplePlasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple MyelomaRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 1

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
RecruitingNCT06623630
Washington University School of MedicineMultiple Myeloma
Start: 2024-12-04End: 2028-05-31Target: 16Updated: 2026-03-11
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
RecruitingNCT07093554
Medical College of WisconsinRefractory Multiple Myeloma, Relapse Multiple Myeloma
Start: 2025-12-02End: 2028-01-01Target: 31Updated: 2026-01-05
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
Not yet recruitingNCT07725406
Weill Medical College of Cornell UniversityRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Start: 2026-08-01End: 2033-08-31Target: 32Updated: 2026-07-24

Phase 2

CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Active, not recruitingNCT05767359
Dana-Farber Cancer InstituteMultiple Myeloma, Smoldering Multiple Myeloma
Start: 2023-04-19End: 2040-01-15Updated: 2026-03-12
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RecruitingNCT06940297
Mayo ClinicRecurrent Multiple Myeloma, Refractory Multiple Myeloma
Start: 2025-09-18End: 2031-08-15Target: 44Updated: 2026-08-26

Unknown Phase

The Norwegian Immunotherapy in Multiple Myeloma Study
RecruitingNCT06855121
St. Olavs HospitalAL Amyloidosis, Myeloma Multiple, Plasma Cell Leukemia
Start: 2025-01-15End: 2037-12-01Target: 400Updated: 2026-07-20

Related Papers

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
2026-04-20
Abstract 6475: Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies
Cancer Research2026-04-03
Abstract 6467: Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy
Cancer Research2026-04-03
Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.
Blood2025-11-03